Hepatitis E virus serum antibodies and RNA prevalence in patients evaluated for heart and kidney transplantation

Alberto Unzueta, Riccardo Valdez, Yu Hui H Chang, Yvonne M. Desmarteau, Raymond L. Heilman, Robert L Scott, David D. Douglas, Jorge Rakela

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background. Acute hepatitis E virus (HEV) infection in solid organ transplant recipients is rare, but can cause severe hepatic and extrahepatic complications. We sought to identify the pretransplant prevalence of HEV infection in heart and kidney candidates and any associated risk factors for infection. Material and methods. Stored frozen serum from patients undergoing evaluation for transplant was tested for HEV immunoglobulin G (IgG) antibodies and HEV RNA. All patients were seen at Mayo Clinic Hospital, Phoenix, Arizona, with 333 patients evaluated for heart (n = 132) or kidney (n = 201) transplant. HEV IgG antibodies (anti-HEV IgG) were measured by enzyme-linked immunosorbent assay, and HEV RNA by a noncommercial nucleic acid amplification assay. Results. The prevalence of anti-HEV IgG was 11.4% (15/132) for heart transplant candidates and 8.5% (17/201) for kidney transplant candidates, with an overall seroprevalence of 9.6% (32/333). None of the patients tested positive for HEV RNA in the serum. On multivariable analysis, age older than 60 years was associated with HEV infection (adjusted odds ratio, 3.34; 95% CI, 1.54-7.24; P = 0.002). Conclusions. We conclude that there was no evidence of acute HEV infection in this pretransplant population and that older age seems to be associated with positive anti-HEV IgG.

Original languageEnglish (US)
Pages (from-to)33-40
Number of pages8
JournalAnnals of Hepatology
Volume15
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Hepatitis E virus
Heart Transplantation
Kidney Transplantation
RNA
Antibodies
Serum
Immunoglobulin E
Virus Diseases
Immunoglobulin G
Transplants
Kidney
Seroepidemiologic Studies
Nucleic Acids
Anti-Idiotypic Antibodies

Keywords

  • Diagnosis
  • Enzyme-linked immunosorbent assay
  • Epidemiology
  • Nucleic acid amplification techniques
  • Risk Factors

ASJC Scopus subject areas

  • Hepatology

Cite this

Hepatitis E virus serum antibodies and RNA prevalence in patients evaluated for heart and kidney transplantation. / Unzueta, Alberto; Valdez, Riccardo; Chang, Yu Hui H; Desmarteau, Yvonne M.; Heilman, Raymond L.; Scott, Robert L; Douglas, David D.; Rakela, Jorge.

In: Annals of Hepatology, Vol. 15, No. 1, 01.01.2016, p. 33-40.

Research output: Contribution to journalArticle

Unzueta, Alberto ; Valdez, Riccardo ; Chang, Yu Hui H ; Desmarteau, Yvonne M. ; Heilman, Raymond L. ; Scott, Robert L ; Douglas, David D. ; Rakela, Jorge. / Hepatitis E virus serum antibodies and RNA prevalence in patients evaluated for heart and kidney transplantation. In: Annals of Hepatology. 2016 ; Vol. 15, No. 1. pp. 33-40.
@article{c9718ebeb72b4721b041a5115bea5653,
title = "Hepatitis E virus serum antibodies and RNA prevalence in patients evaluated for heart and kidney transplantation",
abstract = "Background. Acute hepatitis E virus (HEV) infection in solid organ transplant recipients is rare, but can cause severe hepatic and extrahepatic complications. We sought to identify the pretransplant prevalence of HEV infection in heart and kidney candidates and any associated risk factors for infection. Material and methods. Stored frozen serum from patients undergoing evaluation for transplant was tested for HEV immunoglobulin G (IgG) antibodies and HEV RNA. All patients were seen at Mayo Clinic Hospital, Phoenix, Arizona, with 333 patients evaluated for heart (n = 132) or kidney (n = 201) transplant. HEV IgG antibodies (anti-HEV IgG) were measured by enzyme-linked immunosorbent assay, and HEV RNA by a noncommercial nucleic acid amplification assay. Results. The prevalence of anti-HEV IgG was 11.4{\%} (15/132) for heart transplant candidates and 8.5{\%} (17/201) for kidney transplant candidates, with an overall seroprevalence of 9.6{\%} (32/333). None of the patients tested positive for HEV RNA in the serum. On multivariable analysis, age older than 60 years was associated with HEV infection (adjusted odds ratio, 3.34; 95{\%} CI, 1.54-7.24; P = 0.002). Conclusions. We conclude that there was no evidence of acute HEV infection in this pretransplant population and that older age seems to be associated with positive anti-HEV IgG.",
keywords = "Diagnosis, Enzyme-linked immunosorbent assay, Epidemiology, Nucleic acid amplification techniques, Risk Factors",
author = "Alberto Unzueta and Riccardo Valdez and Chang, {Yu Hui H} and Desmarteau, {Yvonne M.} and Heilman, {Raymond L.} and Scott, {Robert L} and Douglas, {David D.} and Jorge Rakela",
year = "2016",
month = "1",
day = "1",
doi = "10.5604/16652681.1184202",
language = "English (US)",
volume = "15",
pages = "33--40",
journal = "Annals of Hepatology",
issn = "1665-2681",
publisher = "Mexican Association of Hepatology",
number = "1",

}

TY - JOUR

T1 - Hepatitis E virus serum antibodies and RNA prevalence in patients evaluated for heart and kidney transplantation

AU - Unzueta, Alberto

AU - Valdez, Riccardo

AU - Chang, Yu Hui H

AU - Desmarteau, Yvonne M.

AU - Heilman, Raymond L.

AU - Scott, Robert L

AU - Douglas, David D.

AU - Rakela, Jorge

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background. Acute hepatitis E virus (HEV) infection in solid organ transplant recipients is rare, but can cause severe hepatic and extrahepatic complications. We sought to identify the pretransplant prevalence of HEV infection in heart and kidney candidates and any associated risk factors for infection. Material and methods. Stored frozen serum from patients undergoing evaluation for transplant was tested for HEV immunoglobulin G (IgG) antibodies and HEV RNA. All patients were seen at Mayo Clinic Hospital, Phoenix, Arizona, with 333 patients evaluated for heart (n = 132) or kidney (n = 201) transplant. HEV IgG antibodies (anti-HEV IgG) were measured by enzyme-linked immunosorbent assay, and HEV RNA by a noncommercial nucleic acid amplification assay. Results. The prevalence of anti-HEV IgG was 11.4% (15/132) for heart transplant candidates and 8.5% (17/201) for kidney transplant candidates, with an overall seroprevalence of 9.6% (32/333). None of the patients tested positive for HEV RNA in the serum. On multivariable analysis, age older than 60 years was associated with HEV infection (adjusted odds ratio, 3.34; 95% CI, 1.54-7.24; P = 0.002). Conclusions. We conclude that there was no evidence of acute HEV infection in this pretransplant population and that older age seems to be associated with positive anti-HEV IgG.

AB - Background. Acute hepatitis E virus (HEV) infection in solid organ transplant recipients is rare, but can cause severe hepatic and extrahepatic complications. We sought to identify the pretransplant prevalence of HEV infection in heart and kidney candidates and any associated risk factors for infection. Material and methods. Stored frozen serum from patients undergoing evaluation for transplant was tested for HEV immunoglobulin G (IgG) antibodies and HEV RNA. All patients were seen at Mayo Clinic Hospital, Phoenix, Arizona, with 333 patients evaluated for heart (n = 132) or kidney (n = 201) transplant. HEV IgG antibodies (anti-HEV IgG) were measured by enzyme-linked immunosorbent assay, and HEV RNA by a noncommercial nucleic acid amplification assay. Results. The prevalence of anti-HEV IgG was 11.4% (15/132) for heart transplant candidates and 8.5% (17/201) for kidney transplant candidates, with an overall seroprevalence of 9.6% (32/333). None of the patients tested positive for HEV RNA in the serum. On multivariable analysis, age older than 60 years was associated with HEV infection (adjusted odds ratio, 3.34; 95% CI, 1.54-7.24; P = 0.002). Conclusions. We conclude that there was no evidence of acute HEV infection in this pretransplant population and that older age seems to be associated with positive anti-HEV IgG.

KW - Diagnosis

KW - Enzyme-linked immunosorbent assay

KW - Epidemiology

KW - Nucleic acid amplification techniques

KW - Risk Factors

UR - http://www.scopus.com/inward/record.url?scp=84949309539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949309539&partnerID=8YFLogxK

U2 - 10.5604/16652681.1184202

DO - 10.5604/16652681.1184202

M3 - Article

VL - 15

SP - 33

EP - 40

JO - Annals of Hepatology

JF - Annals of Hepatology

SN - 1665-2681

IS - 1

ER -